Search Results - "Whitmore, James"

Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial by Schellhammer, Paul F, Chodak, Gerald, Whitmore, James B, Sims, Robert, Frohlich, Mark W, Kantoff, Philip W

“…Objective To explore the prognostic and predictive value of baseline variables in 512 patients with metastatic castration-resistant prostate cancer from the…”
Get full text

Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials by Li, Daniel H, Whitmore, James B, Guo, Wentian, Ji, Yuan

“…Recent trials of adoptive cell therapy (ACT), such as the chimeric antigen receptor (CAR) T-cell therapy, have demonstrated promising therapeutic effects for…”
Get full text

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer by Sheikh, Nadeem A., Petrylak, Daniel, Kantoff, Philip W., dela Rosa, Corazon, Stewart, Frances P., Kuan, Ling-Yu, Whitmore, James B., Trager, James B., Poehlein, Christian H., Frohlich, Mark W., Urdal, David L.

“…Purpose Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for treatment of advanced prostate cancer, is manufactured by activating…”
Get full text

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome by GuhaThakurta, Debraj, Sheikh, Nadeem A, Fan, Li-Qun, Kandadi, Harini, Meagher, T Craig, Hall, Simon J, Kantoff, Philip W, Higano, Celestia S, Small, Eric J, Gardner, Thomas A, Bailey, Kate, Vu, Tuyen, DeVries, Todd, Whitmore, James B, Frohlich, Mark W, Trager, James B, Drake, Charles G

“…Antitumor activity of cancer immunotherapies may elicit immune responses to nontargeted (secondary) tumor antigens, or antigen spread. We evaluated humoral…”
Get full text

T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy by Martin, Lisa J., Whitmore, James B., Shen, Rhine R., Neumann, Frank

Get full text

Anemia and its relationship to clinical outcome in heart failure by Anand, Inder, McMurray, John J V, Whitmore, James, Warren, Marshelle, Pham, Anh, McCamish, Mark A, Burton, Paul B J

“…Anemia is often observed in patients with chronic heart failure (CHF), but its implications for patient outcomes are not well understood. The goal of this…”
Get full text

Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer by Hall, Simon J, Klotz, Laurence, Pantuck, Allan J, George, Daniel J, Whitmore, James B, Frohlich, Mark W, Sims, Robert B

“…We describe the safety of sipuleucel-T using an integrated analysis of 4 randomized, controlled studies in patients with prostate cancer. Adverse events,…”
Get more information

Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience by MORELAND, Larry W, WEINBLATT, Michael E, KEYSTONE, Edward C, KREMER, Joel M, MARTIN, Richard W, SCHIFF, Michael H, WHITMORE, James B, WHITE, Barbara W

“…OBJECTIVE: To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug (DMARD) refractory rheumatoid…”
Get full text

Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy by George, Daniel J, Nabhan, Chadi, DeVries, Todd, Whitmore, James B, Gomella, Leonard G

“…Sipuleucel-T is an autologous cellular immunotherapy for asymptomatic/minimally symptomatic metastatic castrate-resistant prostate cancer (CRPC). After disease…”
Get more information

Share your views on key concerns

Get full text

Active allyship: helping everyone to thrive in the workplace by Whitmore, James

“…As LGBT+ History Month kicks off, BVLGBT+ president James Whitmore explains how the whole profession can help foster inclusive workplaces through active…”
Get full text

Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer by Kantoff, Philip W, Higano, Celestia S, Small, Eric J, Whitmore, James B, Frohlich, Mark W, Schellhammer, Paul F

Get full text

Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept by MEASE, Phillip J, RITCHLIN, Christopher T, MARTIN, Richard W, GOTTLIEB, Alice B, BAUMGARTNER, Scott W, BURGE, Daniel J, WHITMORE, James B

“…OBJECTIVE: Therapeutics used to treat inflammatory diseases, including psoriatic arthritis (PsA), may potentially interfere with normal immune system function…”
Get full text

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis by GENOVESE, Mark C, BATHON, Joan M, FLEISCHMANN, Roy M, MORELAND, Larry W, MARTIN, Richard W, WHITMORE, James B, TSUJI, Wayne H, LEFF, Jonathan A

“…OBJECTIVE: To evaluate safety, efficacy, and radiographic progression in patients with early rheumatoid arthritis (RA) undergoing longterm treatment with…”
Get full text

Pride is a movement, not just a moment by Whitmore, James

“…June saw the nationwide celebration of Pride Month. BVLGBT+ president James Whitmore reflects on the origins of Pride events and the reason they're still…”
Get full text

Recognising workplaces prioritising team wellbeing

Get full text

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma by Borish, Larry C., Nelson, Harold S., Corren, Jonathan, Bensch, George, Busse, William W., Whitmore, James B., Agosti, Jan M.

“…Background: IL-4 mediates important proinflammatory functions in asthma, including induction of the IgE isotype switch, increased expression of vascular cell…”
Get full text

Celebrating LGBT+ History Month 2023 by Whitmore, James

“…As LGBT+ History Month kicks off, BVLGBT+ president James Whitmore introduces the society's role model campaign…”
Get full text

Quality of Life After Sipuleucel-T Therapy: Results From a Randomized, Double-blind Study in Patients With Androgen-dependent Prostate Cancer by Beer, Tomasz M, Schellhammer, Paul F, Corman, John M, Glodé, L. Michael, Hall, Simon J, Whitmore, James B, Frohlich, Mark W, Penson, David F

“…Objective To collect and analyze quality-of-life (QOL) data from PROvenge Treatment and Early Cancer Treatment trial (PROTECT, NCT00779402 ), a phase III,…”
Get full text

Interleukin-4 receptor in moderate atopic asthma: A phase I/II randomized, placebo-controlled trial by BORISH, L. C, NELSON, H. S, LANZ, M. J, CLAUSSEN, L, WHITMORE, J. B, AGOSTI, J. M, GARRISON, L

“…Interleukin-4 mediates important proinflammatory functions in asthma, including induction of the IgE isotype switch, expression of VCAM-1 on endothelium, mucin…”
Get full text